The increased income was driven by revenues and gross margin increases as a result of the company’s direct operation transitions and international markets. Research and development expenses increased 18 percent to $2.1 million, prompting a 29 percent increase in operating profit.
The company’s knee implant revenue increased 1 percent to $21.5 million while the revenue from extremities and hip business lines both increased 37 percent. Conversely, the company’s spine and biologic revenue decreased 13 percent to $6.2 million.
More Articles on Orthopedic Device Companies:
DJO Global Net Sales Jump 11.7%
Zimmer’s Q1 Hip & Knee Sales Up 2%, Spine Sales Drop
Orthofix Net Sales Reach $143.1M, Spine Sales Grow 3%
